Navigation Links
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:2/25/2008

MOUNTAIN VIEW, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has initiated its first Phase 3 clinical trial with AZ-004 (Staccato(R) loxapine). AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. Alexza believes the novel, non-invasive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a viable product to treat acute agitation. AZ-004 is being developed through Symphony Allegro, a product development partnership formed between Alexza and Symphony Capital, LLC.

"We are excited to be initiating our AZ-004 NDA plan with this first Phase 3 clinical trial," said Thomas B. King, Alexza President and CEO. "The results we have seen to date with AZ-004 have been promising and we look forward to enrolling the planned Phase 3 clinical trials as quickly as possible. This is a transitional year in our history as we move into the early commercial planning for the manufacturing, regulatory submissions, and potential sales and marketing of AZ-004."

AZ-004 Phase 3 Clinical Trial Design

The first AZ-004 Phase 3 clinical trial is designed to enroll approximately 300 schizophrenic patients with acute agitation at 25 U.S. clinical centers. The trial is an in-clinic, multi-center, randomized, double-blind, placebo-controlled study and will test AZ-004 at two dose levels, 5 and 10 mg. Patients may receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status.

The primary endpoint for the study is the change from baseline in the PANSS (Positive and
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Boston, MA (PRWEB) April 28, 2015 ... the science of the little-known and incurable disease, ... awarded $485,840 in grants to new projects in the ... and children around the world. , The FSH Society’s ... proposals for the grants. They awarded monies to projects ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 CargoSense, ... company focused on supply chain logistics, today announced ... its seed round, bringing total investment proceeds to ... early stage venture capital firms IrishAngels and Middleburg ... Innovative Technology, also participated in the round. ...
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... its participation in the upcoming Labroots virtual ... May 13-14, 2015. The theme of this ... genomics topics such as RNAi, Next-generation sequencing, ... epigenetics, mapping, exomes, genomic medicine, human Genome ...
(Date:4/28/2015)... April 28, 2015 Showcasing continued ... a relationship marketing company that provides scientifically advanced, ... of the Direct Selling Association (DSA) by the ... minimum one-year review period, the DSA confirmed that ... and expectations of the association: to ensure that ...
Breaking Biology Technology:FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 2FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 3FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 4CargoSense Completes Seed Round Offering By Raising $2.5 Million 2CargoSense Completes Seed Round Offering By Raising $2.5 Million 3CargoSense Completes Seed Round Offering By Raising $2.5 Million 4Pittcon Announces Plans to Exhibit at the Annual Labroots Genetics and Genomics Virtual Event 2Pittcon Announces Plans to Exhibit at the Annual Labroots Genetics and Genomics Virtual Event 3Nerium International Receives Direct Selling Association Membership 2Nerium International Receives Direct Selling Association Membership 3
... of our nation,s long-term clean-energy future, but the technology ... Japan,s recent Fukushima disaster. Indeed, many nations have called ... are operating safely. In the United States, ... percent of the electricity from emission-free sources, including renewable ...
... Mediabrands, IPG Media Lab and Affectiva today announced, ... results of the first annual Neuromarketing Awards. Utilizing ... record and measure viewers, tacit, non-verbal response to ... features are established and are then measured and ...
... ,   The randomised, ... efficacy and safety of,the monoclonal antibody rituximab (RTX) ... that in patients with,severe AAV a single course ... period of 18 months proved to be as ...
Cached Biology Technology:Berkeley scientists pioneer nanoscale nuclear materials testing capability 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3ERA-EDTA Congress 2011: Late Breaking Clinical Trials I 2
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... , This release is available in ... the Tulane University School of Medicine, in New ... major component of black seed oil ( Nigella ... aggressive prostate cancer (PCa) cell lines, in vitro. ...
... widely known for precisely positioning and sculpting various organs ... that could be useful for understanding the explosive growth ... are being born with genital and urinary tract malformations. ... Communications , researchers at the University of Florida say ...
... The International Institute for Species Exploration at Arizona State University ... calendar year. The list for 2009 was published to coincide ... of Carl Linnaeus. It contains only two new plant species, ... Journal of the Linnean Society . Nepenthes ...
Cached Biology News:Thymoquinone induced oxidative stress targets highly aggressive prostate cancers 2Sluggish cell division may help explain genital defects 2Sluggish cell division may help explain genital defects 3Sluggish cell division may help explain genital defects 4Rare carnivorous plant on top 10 list of newly discovered species 2